Potassium Management in ESRD Patients

Introduction to Potassium Binders

The American College of Cardiology recommends the use of sodium zirconium cyclosilicate (SZC/Lokelma) and patiromer (Veltassa) for managing chronic hyperkalemia in patients with end-stage renal disease (ESRD), with SZC offering faster onset and patiromer providing sustained control 1, 2

For acute management, initial dosing of 10 g SZC three times daily for up to 48 hours produces a mean potassium reduction of 1.1 mEq/L, with onset of action within 1 hour 1, 3
The dose-dependent response of SZC shows exponential rates of change: 0.30% with 10 g, 0.21% with 5 g, 0.16% with 2.5 g, and 0.11% with 1.25 g 1, 3
For chronic management in non-dialysis ESRD, 10 g SZC once daily is recommended, adjustable by 5 g increments at weekly intervals to maintain potassium 3.5-5.0 mEq/L 1
90% of patients maintained normokalemia on 10 g SZC daily over 28 days in clinical trials 3
SZC works in both small and large intestines, unlike other binders that work primarily in the colon, and is more selective for potassium than SPS or patiromer 3
Patiromer has an initial dose of 8.4 g twice daily for moderate hyperkalemia (K+ 5.5-6.0 mEq/L), producing mean reductions of 0.87-0.97 mEq/L 1

The American Heart Association recommends separating other oral medications by at least 2-3 hours when using newer potassium binders to avoid reduced absorption 3
SZC contains approximately 400 mg sodium per 5 g dose, requiring monitoring for edema in patients requiring sodium restriction 3

The European Society of Cardiology recommends maintaining cardioprotective medications, with 86% of patients remaining on spironolactone with patiromer versus 66% with placebo (P<0.0001) 1
The American College of Cardiology recommends not discontinuing RAAS inhibitors for hyperkalemia, instead initiating potassium binders to optimize cardioprotective therapy 5, 2, 3, 4

Edema is the most common adverse effect with SZC, occurring in 6% at 10 g daily and 14% at 15 g daily 3

The National Kidney Foundation recommends avoiding the use of SPS chronically due to gastrointestinal toxicity risk despite decades of historical use 1, 2
The American College of Cardiology recommends not discontinuing RAAS inhibitors prematurely, as the newer binders enable continuation of these cardioprotective medications 5, 2, 7, 4